childhood acute promyelocytic leukemia
Conditions
Interventions
high-risk group:ATRA+ATO/RIF+chemotherapy
Sponsors
Beijing Children's Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed of APL; 2. Patients younger than 18 years old; 3. Patients with normal heart function; 4. Patients who have signed the Informed Consent Form.
Exclusion criteria
Exclusion criteria: 1. Patient diagnosed of APL relapsed after using arsenical; 2. Be allergic to arsenical; 3. The family members couldn't understand or follow the trial; 4. Contraindications of using anthracycline-based chemotherapy drugs; 5. Other situations that hinder the research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hematologic complete remission;Molecular complete remission;Event-free survival;overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| cumulative disease rate of relapse;early mortality rate; | — |
Countries
China
Contacts
Public ContactHuyong Zheng
Beijing Children's Hospital, Capital Medical University
Outcome results
None listed